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Table. Base-Case Estimates of 5-Year Treatment Costs and Quality-Adjusted
Life-Years
Treatment
Strategy Germany Italy France Spain
The
Netherlands
Universal
Ticagrelor
Costs (V) 19,611 19,806 19,287 19,355 19,058
QALYs 3.919 3.858 3.764 3.822 3.910
PRA-Driven
Ticagrelor
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S24 and 72h after the switch, and veriﬁed through standard Light Transmission
Aggregometry (LTA).
Results: No relevant difference in platelet aggregation between the two study arms
was observed at baseline (p¼0.256). Residual platelet aggregation measured using
MEA was signiﬁcantly reduced in both arms 2h after the ﬁrst administration of TICA
(both p<0.001). Most interestingly, no difference in aggregation was found 2 hours
after the switch to TICA (17672 vs 18160 AUmin, p¼0.281). Similar ﬁndings
were conﬁrmed with LTA.
Conclusions: Switching from ongoing CLO therapy to TICA without a loading dose
is safe and is not associated to a lower degree of PLT inhibition in patients with ACS.
Larger trials are needed to conﬁrm the present results on a clinical endpoint, as
incidence of bleedings.Costs (V) 19,195 19,168 18,965 18,851 18,633
QALYs 3.910 3.849 3.756 3.814 3.902
ICER vs. PRA-
Driven
Ticagrelor
46,222 70,889 40,250 63,000 53,125
Universal
Prasugrel
Costs (V) 19,636 19,373 19,059 19,034 18,934
QALYs 3.875 3.815 3.722 3.780 3.867
PRA-Driven
Prasugrel
Costs (V) 19,205 18,984 18,867 18,715 18,581
QALYs 3.891 3.831 3.738 3.796 3.883
ICER vs. PRA-
Driven
Prasugrel
Dominated Dominated Dominated Dominated Dominated
ICER¼incremental cost-effectiveness ratio; QALY¼quality-adjusted life-year; PRA¼platelet
reactivity assay; V¼EurosTCT-162
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Background: Platelet reactivity assays (PRAs) can predict patients' likely response to
clopidogrel. We assessed the cost-effectiveness of universal compared to PRA-driven
selection of ticagrelor or prasugrel for acute coronary syndrome (ACS) patients living
in multiple European countries.
Methods: An Markov model was used to calculate 5-year costs (2013V), quality-
adjusted life-years and incremental cost-effectiveness ratios (ICERs) for 1-year of
universal ticagrelor or prasugrel (given to all) compared to each agents' corresponding
PRA-driven strategy (ticagrelor/prasugrel in those with high platelet reactivity [HPR,
>208 on the VerifyNow P2Y12 assay, Accumetrics, San Diego, CA], others given
generic clopidogrel]. We assumed patients had their index ACS event at 65-70 years
of age and had a 42.7% incidence of HPR post-revascularization. The analysis was
conducted from the perspective of 5 different European countries (Germany, Italy,
France, Spain and The Netherlands) and used a 1-year cycle length. Efﬁcacy and
safety data for P2Y12 Inhibitors were taken from multinational randomized trials and
adjusted using country-speciﬁc epidemiologic data.
Results: Neither universal ticagrelor nor prasugrel were found to be cost-effective (all
ICERs >40,250V/QALY) compared to their corresponding PRA-driven strategies in
any of the countries evaluated (Table). Results were sensitive to differences in P2Y12
Inhibitors costs and drug-speciﬁc relative risks of major adverse cardiac events. Monte
Carlo simulation suggested universal ticagrelor or prasugrel were cost-effective in
only 29-44% and 11-17% of 10,000 iterations compared to their respective PRA-
driven strategies, when applying a willingness-to-pay threshold¼V30,000/QALY.B52 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: The universal use of newer P2Y12 inhibitors is not likely cost-effective
compared to PRA-driven strategies.
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Background: Paroxysmal atrial ﬁbrillation (AF) is frequent in patients undergoing
percutaneous coronary intervention (PCI), but optimum antithrombotic therapy has
not been deﬁned, and whether patients with paroxysmal AF in sinus rhythm (SR) at
the time of PCI require anticoagulation concurrent with DAPT is unknown.
Methods:We evaluated 291 consecutive patients from 2 university Hospitals (US and
Europe), with paroxysmal non-valvular AF who were in SR at the time of PCI
between 2009 and 2011 prescribed triple (TT, n¼98; 34%) or dual antithrombotic
therapy (DAPT, n¼193; 66%) post PCI and compared rates of major adverse
cardiovascular events (MACCE ¼ death, myocardial infarction [MI], revasculariza-
tion, stroke, peripheral embolism or stent thrombosis) in patients on DAPT (aspirin +
clopidogrel), vs. TT (DAPT + oral anticoagulant).
Results: Baseline characteristics in the TT and DAPT groups were similar for age (72
 9 vs. 70  10 years; P¼0.25), gender (29 vs. 27% females, P¼0.73),
CHA2DS2VASc score >1 (91 vs. 86%, P¼0.25), and ejection fraction <30% (12 vs.
9%, P¼0.34). The TT group had shorter lesions and stents compared to those on
DAPT (25  19 vs. 30  19 mm, P¼0.02). Mean duration of clopidogrel therapy was
similar, as was the use of bare-metal stents. At 1-year, rates of MACCE (22 vs. 20%;
P¼0.71, Figure 1.), stroke (1.2 vs. 0.6%, P¼0.13); major bleeding (3 vs. 1%, P¼0.37)ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
